Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neuronetics, Inc. filings document the public reporting record for a Nasdaq-listed medical technology and healthcare company with common stock traded under STIM. Recent Form 8-K reports furnish operating results, investor presentation materials, executive appointments and retirements, compensation arrangements, restructuring charges, and material agreements tied to credit facilities and registration rights.
The company’s proxy materials describe annual meeting voting matters, director elections, auditor ratification, advisory executive compensation votes, and equity incentive plan approvals. Together with event reports, the filings disclose governance procedures, capital-structure matters, Nasdaq-listed security information, and contractual obligations associated with Neuronetics’ medical device and clinic-services operations.
Neuronetics, Inc. director Avinash Amin reported internal share transfers among affiliated investment funds, with no open‑market buying or selling. On 2026-06-15, Amin transferred 4,634 shares of common stock to Madryn Health Partners II, LP, 34,932 shares to Madryn Health Partners II (Cayman Master), LP, and 2,934 shares to Madryn Select Opportunities, LP.
The footnotes state these transfers involved shares received as director compensation and were made for no consideration, as provided in each fund’s partnership agreement. After these J-code restructuring transactions, Amin directly holds 69,566 shares of Neuronetics common stock.
Neuronetics, Inc. insider filing reports internal share transfers among investment funds advised by Madryn Asset Management related to director compensation. On May 28 and June 15, entities associated with Madryn reallocated a total of 72,500 shares of common stock, all coded as other acquisitions or dispositions.
The shares originated from restricted stock units awarded to director Avinash Amin, which are held for the benefit of Madryn Health Partners II, Madryn Health Partners II (Cayman Master), and Madryn Select Opportunities under their partnership agreements. Each transfer was made for no consideration and reflects reallocations among these funds rather than open‑market trades.
After these transactions, indirect holdings reported include 2,269,073 shares for one Madryn fund, 17,104,530 shares for another, and 1,435,958 shares for a third. The reporting persons state that they may be deemed to beneficially own these shares through advisory and general partner roles, but each disclaims beneficial ownership except to the extent of any pecuniary interest.
STIM submitted a Form 144 notice reporting a proposed sale of 42,164 shares of Common Stock associated with restricted stock vesting. The filing lists a broker-dealer, Fidelity Brokerage Services LLC, and an intended transaction date of 06/08/2026. It also discloses prior sales of 46,289 shares on 03/19/2026 by Keith Sullivan.
Neuronetics, Inc. director Megan Rosengarten reported receiving an award of 30,000 restricted stock units of common stock. The RSU grant is a form of equity compensation and carries no cash exercise price.
The award vests on the earlier of May 28, 2027, or her Board-approved separation of service or a change in control of Neuronetics, in each case requiring her continuous service through that date. After this grant, she holds 170,890 shares and RSUs of Neuronetics common stock directly.
Neuronetics, Inc. director Glenn P. Muir received a grant of 30,000 restricted stock units (RSUs) of common stock at no cost. The RSU award vests on the earlier of May 28, 2027, or a Board-approved separation of service or change in control, subject to his continuous service.
Each RSU converts into one share of Neuronetics common stock when it vests. Following this equity award, Muir’s reported direct holdings increased to 401,816 shares of common stock.
Cucuz Sasha reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. director Sasha Cucuz received an award of 30,000 restricted stock units (RSUs) of common stock. The RSUs vest on the earlier of May 28, 2027 or a Board-approved separation of service or change in control, in each case requiring continuous service until that date.
Each RSU represents a contingent right to receive one share of Neuronetics common stock. Following this grant, Cucuz directly holds 1,542,798 shares. Separate indirectly held shares are reported as held by Greybrook Health Inc. (516,084 shares) and Greybrook Realty Partners Inc. (2,042 shares), with beneficial ownership of these indirect holdings disclaimed except to the extent of his pecuniary interest.
CONLEY SHERYL L reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. director Sheryl L. Conley reported receiving an equity award in the form of restricted stock units. The award covers 30,000 RSUs, with no cash purchase price. Each RSU represents the right to receive one share of Neuronetics common stock.
The RSUs vest on the earlier of May 28, 2027, or her Board-approved separation from service or a change in control of Neuronetics, in each case conditioned on her continuous service through that date. After this grant, Conley holds 251,716 shares of common stock directly.
Neuronetics, Inc. director Robert Cascella received a grant of 36,250 restricted stock units of common stock as equity compensation. The award has no cash exercise price and will vest on the earlier of May 28, 2027, or a Board-approved separation or change in control, subject to his continuous service. After this grant, Cascella holds 625,017 shares of Neuronetics common stock directly.
Neuronetics, Inc. director Avinash Amin reported an equity compensation grant in the form of 30,000 restricted stock units of common stock. The award vests on the earlier of May 28, 2027, a Board-approved separation of service, or a change in control, in each case subject to his continuous service. Each RSU converts into one share of common stock upon vesting. Following this grant, he holds 72,500 shares directly.
Neuronetics, Inc. reported the voting results from its Annual Meeting of Stockholders. A total of 55,950,118 shares of common stock, representing approximately 80.41% of shares outstanding and eligible to vote, were present in person or by proxy, establishing a quorum.
All seven director nominees were elected to one-year terms with individual support levels ranging from about 28.5 million to 34.5 million votes. Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
On a non-binding advisory basis, stockholders approved executive compensation with 29,133,360 votes for and 11,503,294 against. They also approved the Neuronetics, Inc. 2026 Equity Incentive Plan, which received 23,802,955 votes for and 16,651,661 against, with additional abstentions and broker non-votes on both proposals.